Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI2228 in Relapsed/Refractory Multiple Myeloma
NCT03489525Phase 1Completed
- Sponsor
- MedImmune
- Start
- May 2018
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of MEDI2228 in multiple myeloma (MM) (2 arms), sponsored by MedImmune. Primary endpoints: Occurrence of adverse events, Occurrence of serious adverse events and 4 more. Started May 2018; status: completed.
02
Drugs
MEDI2228
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03489525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489525.